HUTCHMED and AstraZeneca Submit US NDA for Lung Cancer Combination Therapy
Event summary
- HUTCHMED and AstraZeneca submitted a US NDA for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) to treat MET-driven EGFR-mutated lung cancer.
- The NDA is supported by the SAFFRON Phase III trial, showing statistically significant improvements in PFS and OS.
- SAFFRON enrolled 338 patients across 230 centers in 29 countries.
- ORPATHYS® is already approved in China for NSCLC with MET exon 14 skipping alteration and in combination with TAGRISSO® for EGFR-mutated NSCLC with MET amplification.
- Results from SAFFRON will be presented at the ESMO Congress 2026.
The big picture
The submission of the US NDA for ORPATHYS® plus TAGRISSO® marks a significant step in addressing MET-driven resistance in EGFR-mutated lung cancer, a common and challenging mechanism of treatment failure. The success of the SAFFRON trial underscores the growing importance of biomarker-directed therapies in oncology, particularly in precision medicine. HUTCHMED's collaboration with AstraZeneca highlights the strategic value of partnerships in developing and commercializing targeted cancer therapies.
What we're watching
- Regulatory Timing
- The pace at which the FDA reviews the NDA will determine the US launch timeline for ORPATHYS® plus TAGRISSO®.
- Commercial Strategy
- How HUTCHMED and AstraZeneca position the combination therapy against existing treatments for MET-driven EGFR-mutated lung cancer.
- Global Expansion
- Whether the positive SAFFRON results will accelerate regulatory filings in other major markets beyond the US and China.
Related topics